Intellia Therapeutics (NTLA) Other Operating Expenses (2024 - 2026)

Intellia Therapeutics (NTLA) has 3 years of Other Operating Expenses data on file, last reported at $904000.0 in Q1 2026.

• Other Operating Expenses for Q1 2026 came in at $904000.0, down 57.46% year-over-year; the trailing twelve-month figure through Mar 2026 was -$2.1 million (up 94.19% YoY), and the FY2025 annual result was -$899000.0, up 97.24% from the prior year.
• Other Operating Expenses retreated to $904000.0 in Q1 2026 per NTLA's latest filing, from $1.8 million in the prior quarter.
• Over five years, Other Operating Expenses peaked at $20.4 million in Q2 2024 and troughed at -$62.0 million in Q4 2024.
• A 3-year average of -$3.6 million and a median of $1.8 million in 2025 frame the typical range for Other Operating Expenses.
• On a YoY basis, Other Operating Expenses climbed as much as 102.83% in 2025 and fell as far as 212.24% in 2025.
• A 3-year view of Other Operating Expenses shows it stood at -$62.0 million in 2024, then soared by 102.83% to $1.8 million in 2025, then plunged by 48.46% to $904000.0 in 2026.
• Business Quant data shows NTLA's Other Operating Expenses at $904000.0 in Q1 2026, $1.8 million in Q4 2025, and -$3.4 million in Q3 2025.